Autoimmunity is an integral part of immune dysregulation in a quarter of patients with common variable immunodeficiency (CVID), often presenting as the first manifestation of the disease ([@B1]). In recent years analyses of the immune disturbances have revealed complex dysregulations of the immune system. In parallel, progress in our comprehension of the pathogenesis of connective tissue disorders like systemic lupus erythematosus (SLE) allows for comparison of common roots of human autoimmune (AI) disorders.

This perspective article is an attempt to summarize the factors which contribute to autoimmunity in CVID.

Autoimmune cytopenias are the most common AI manifestations in CVID and the focus of this article. In the context of distinct associated alterations of the cellular immune system AI cytopenias appear to be a separate manifestation from organ-specific autoimmunity in CVID ([@B5]; [@B10]). The presentation of AI-CVID patients resembles patients with autoimmune lymphoproliferative syndrome (ALPS) with the coincidence of lymphoproliferation and AI cytopenias ([@B61]; [@B77]; [@B5]). While none of the cellular markers, such as increased double negative T cells or reduced switched memory B cells, helped to distinguish AI-CVID from FAS-ALPS, increased serum levels of soluble Fas ligand, interleukin (IL) 10, and vitamin B12 allowed a distinction between FAS-ALPS patients and AI-CVID to be made ([@B53]). None of the tested CVID patients carried a genomic or somatic mutation in FAS, rendering FAS-ALPS a differential diagnosis. Thus, the reason that lymphoproliferation and autoimmunity are seen together in most of the CVID patients remains obscure. Other causes of ALPS and ALPS-related disorders have not been excluded systematically in AI-CVID.

Other immunodeficiencies strongly associated with AI manifestations comprise immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome, autoimmune polyendocrine syndrome type 1, combined immunodeficiencies (CID) including hypomorphic severe (S)CID variants ([@B37]), both calcium channelopathies, Wiskott--Aldrich syndrome (WAS), DiGeorge syndrome, Good syndrome, activation-induced deaminase (AID) deficiency, CD25 deficiency, Stat5b deficiency, and cartilage hair dysplasia ([@B2]).

Most of these immunodeficiencies are associated with (i) disturbed T cell homeostasis, (ii) altered antigen receptor, or (iii) altered cytokine signaling. Aspects relevant in patients with CVID shall be discussed in the following sections.

DISTURBED T CELL HOMEOSTASIS IN AI-CVID
=======================================

Disturbed T cell homeostasis is a common contributing factor to the development of autoimmunity in different forms of monogenic primary immunodeficiency disorders (PIDs). Several features of disturbed cell homeostasis are also present in CVID. Lymphopenia affects mostly CD4 T cells and especially naïve CD4 T cells, while CD8 T cells become relatively expanded ([@B25]). Both CD4 and CD8 T cells are activated as determined by the expression of activation markers and Ki67. Thymic output was decreased, but Ki67 expression was particularly strong in naïve and central memory T cells, suggesting homeostatic proliferation as described for other immunodeficiency models ([@B9]). In addition, the Vβ repertoire of CD4 T cells had contracted. These changes are well known to be associated with an increased risk of autoimmunity as previously demonstrated in murine models and human AI disease ([@B13]).

The severe reduction in naïve CD4 T cells in CVID has been suggested as a criterion for the diagnosis of late-onset CID (LOCID; [@B40]) for resembling the immunological and clinical phenotype of patients with hypomorphic SCID mutations ([@B37]; [@B9]; [@B14]). Interestingly, the association of CD4 lymphopenia in primary immunodeficiency seems to be stronger with granulomatous inflammatory disease than AI cytopenias ([@B58]; [@B45]). IL-7, which has a key role in the expansion of autoreactive T cell clones in the lymphopenic host, was also found to be elevated in a subgroup of CVID patients ([@B29]). Though increased IL-7 levels were not associated with T cell lymphopenia, they nevertheless correlated with a more frequent incidence of autoimmunity. The regular feedback mechanism of IL-7 regulation seemed to fail in the small group of AI-CVID patients examined. The production of several other cytokines including IL-2, interferon (IFN)-γ, IL-4, and TNFα is altered in some CVID patients, but none of the reported alterations have been examined for their role in eliciting autoimmunity ([@B19]; [@B23]; [@B46]). Testing the role of specific cytokines in this setting will be of great interest as it is likely to reveal potential therapeutic targets.

Skewing of CD8 T cells is often more prominent than that of CD4 T cells ([@B25]). Cytomegalovirus (CMV) causes immunosenescence associated with terminal differentiation of CD8 effector T cells which results in a skewing of the repertoire. In CVID this phenomenon was exaggerated ([@B36]). A chronic viral infection is therefore a potential trigger for the clinical manifestation of AI disease in a disturbed immune system ([@B41]).

Selection, activation, and differentiation of T cells in CVID may also be affected by an impaired response of the T cell receptor after stimulation ([@B19]; [@B7]; [@B47]). However, to date, the published investigations neither report an underlying genetic defect nor a correlation between altered T cell receptor signaling and a higher prevalence of autoimmunity. Currently, the only intrinsic T cell defect which causes CVID was found in a total of 11 patients with deficiency of the inducible costimulator (ICOS; [@B73]; [@B63]). Only one of the original nine European patients presented with AI neutropenia, whereas AI manifestations were more prominent in the two Japanese patients presenting with (rheumatoid) arthritis, inflammatory bowel disease, interstitial pneumonitis, and psoriasis.

Finally, many reports have described reduced numbers of circulating regulatory T cells in CVID, especially affecting Freiburg Ia patients with reduced switched memory B cells and expansion of CD21^low^ B cells (see below; [@B18]; [@B24]; [@B30]; [@B44]; [@B79]; [@B3]; [@B45]). Several of the factors mentioned above, such as a CID-like phenotype with or without a disturbed TCR signal ([@B49]; [@B57]), cytokine disturbance ([@B60]), and even persistent CD4 lymphopenia itself ([@B42]) might contribute to the reduction in regulatory T cells. Interestingly, even ICOS deficiency disturbs maintenance and function of regulatory T cells ([@B33]), thus potentially rendering regulatory T cell deficiency a crucial element in AI dysregulation which is also common to different forms of immunodeficiency.

DISTURBED B CELL HOMEOSTASIS IN AI-CVID
=======================================

B cell homeostasis is also disturbed in CVID patients. Therefore, reduced switched memory B cell development and the expansion of activated CD21^low^ B cells are associated with the manifestation of AI-CVID ([@B75]; [@B56]; [@B31]; [@B5]). CD21^low^ B cells contain a high proportion of autoreactive clones ([@B51]; [@B31]) suggesting a disturbed selection of the B cell repertoire. This may involve defects in central selection for some ([@B31]), but not all patients ([@B50]). Several factors have been identified as interfering with B cell selection. Firstly, the signal strength of the BCR itself determines the outcome during selection ([@B32]). Several mouse models have demonstrated that alterations in the signaling machinery ([@B12]; [@B72]) and the balance between co-stimulatory ([@B64]) and inhibitory co-receptors ([@B11]) determine the counter-selection of AI B cell clones. In CVID patients disturbed antigen receptor signaling was described and is discussed below.

Given the negative feedback loop of immune complexes on B cells and plasma cells via the inhibitory receptors ([@B59]; [@B4]) it is intriguing to speculate as to whether low serum IgG by itself may contribute to antibody-mediated AI cytopenias as one of the first manifestations in AI-CVID. Signaling by FcγRIIB inhibits B cell activation and can even induce apoptosis in plasma cells ([@B78]). Additionally, a lack of inhibition of monocytes/macrophages by FcγRIIB may foster overwhelming inflammatory responses and granuloma formation, a serious clinical problem seen in a subset of AI-CVID patients. Lupus-like disease in FcγRIIB-deficient C57BL/6 mice ([@B6]) as well as the increased risk of SLE in homozygous carriers of the dysfunctional FcγRIIB I232T variant ([@B21]) clearly indicate a crucial role for this inhibitory receptor in the maintenance of humoral tolerance. This hypothesis is supported by the fact that in most CVID patients the initiation of immunoglobulin replacement leads to an amelioration of the bouts of AI-mediated cytopenias.

The other major factors, which contribute to B cell-mediated autoimmunity, are related to survival signals during selection ([@B8]). For B cells, overexpression of B cell-activating factor (BAFF) causes increased survival of autoreactive B cells and overt autoimmunity ([@B39]; [@B67]). It is noteworthy that most CVID patients present with elevated BAFF levels ([@B34]). Currently it is unknown whether elevated BAFF levels sustain the expansion of CD21^low^ B cells in CVID. The number of circulating CD21^low^ B cells increases in other AI diseases, such as SLE ([@B76]), rheumatoid arthritis ([@B31]), and cryoglobulinemia ([@B65]), supporting an association with autoimmunity. In contrast to SLE, where switched memory B cells are relatively expanded and active disease is associated with expansion of circulating plasmablasts ([@B15]), AI-CVID has a more severe reduction in the number of switched memory B cells when compared to other CVID patients. This could represent a disturbed peripheral differentiation and selection. Increased autoimmunity associated with poor germinal center function has also been observed in deficiency of the AID ([@B28]), but no abnormalities of AID expression or function have been described in CVID at this point.

Of all the genetic mutations which are associated with CVID, AI manifestations are most common in TACI-deficiency \[18/50 (36%) vs 112/490 (23%) in wt TACI CVID; [@B55]\]. In particular, heterozygous C104R mutations seem to effect a predisposition for autoimmunity (11/20 patients, 55%; [@B55]). While partial TACI signals in a heterozygous state may contribute to the survival of autoreactive B cells, a formal proof of this hypothesis is still missing. AI manifestations including glomerulonephritis and vasculitis (interestingly with deposits of IgA) as well as AI thrombocytopenia (AI-TP) have also been described for CD19 and CD81 deficiency, and are possibly related to the disturbed antigen receptor signal in these patients (see also below; [@B69], [@B70]; [@B71]). The other B cell-intrinsic genetic defects associated with CVID (BAFF-R, CD20, CD21) have not been reported with AI manifestations ([@B74]; [@B35]; [@B66], but to date only single patients have been described for each defect, thus precluding definite conclusions.

In recent years, a B cell population producing IL10 has been described as regulatory B cells ([@B43]). Currently, nothing is known about their existence and function in CVID.

DISTURBED ANTIGEN RECEPTOR SIGNAL IN AUTOIMMUNE CVID
====================================================

Several mouse models of increased BCR signals demonstrate an increased prevalence of AI manifestations ([@B16]). On the other hand, models of decreased TCR signaling can also represent a risk factor for autoimmunity (summarized in [@B37]). Decreased TCR signals are thought to interfere with negative selection either through a selective or a stronger impact on tolerogenic signals ([@B37]) thus potentially impairing the generation of regulatory T cells ([@B38]). In humans, ORAI ([@B17]) and Stim1 deficiency ([@B49]) need to be mentioned as prototypes of reduced antigen receptor signal strongly associated with the coincidence of immunodeficiency and autoimmunity in the affected patients. Also in B cells of the subgroup of CVID patients with an increased risk of AI manifestations, calcium signaling is reduced compared to other CVID patients and healthy controls ([@B22]; [@B68]). The exact mechanism of the signaling defect and its potential interference with selection are unknown. In WAS, antigen receptor signaling is impaired due to mutations in the WAS protein ([@B81]). Interestingly, WASP deficiency also leads to increased AI disease associated with decreased CD27^+^ memory B cells and increased CD21^low^ B cells ([@B48]). Although WASP deficiency affects both T and B cell receptor signaling, B cell-intrinsic defects clearly contribute to autoimmunity in WAS ([@B52]). As indicated above, previous reports have found disturbed TCR-induced calcium signals ([@B20]) in 40--50% of CVID patients but a link to immune dysregulation in the identified patients has not been established.

ALTERED TYPE I INTERFERON SIGNAL IN AUTOIMMUNE CVID
===================================================

Cytokines have been implicated in AI dysregulation. Type I IFNs are thought to be particularly important as (i) AI reactions are induced in patients after treatment with type I IFNs, (ii) the *IFN* signature is increased in patients with SLE, and (iii) some chronic viral infections are associated with autoimmunity ([@B27]). The mechanisms are manifold and include induction of dendritic cell (DC) maturation and increased BAFF production, a positive feed back loop in toll-like-receptors (TLR) 7 and 9 signaling leading to class switched antibody production ([@B27]).

Type I IFNs have not been well examined in CVID patients. There exists only a single report of increased type I IFN production in CVID patients ([@B62]); others have detected increased MxA expression as a marker of IFN exposure in leukocytes of only 2/13 CVID patients ([@B54]). So far no attempt to correlate in CVID IFN expression to AI manifestations has been made.

Type I IFN expression and the induction of AI reactions is closely linked to the activation of TLRs on plasmacytoid DCs (pDCs) and B cells ([@B26]). Different strains of AI prone mice rendered deficient in TLR7/9 or MyD88 expression produce dramatically fewer autoantibodies and develop less severe disease ([@B26]). Surprisingly, however, TLR9 deficiency in the presence of normal TLR7 function reduces only anti double-strain-DNA autoantibody levels, but not other autoantibodies and is associated with a more severe AI disease, suggesting a regulatory role of TLR9 for TLR7-mediated immune disease. In CVID patients, pDC and B cell responses to TLR7 and 9 ligands are impaired ([@B80]). Subanalysis of the reported data suggests that a subgroup of patients is more seriously affected by reduced TLR signaling. While the authors correlate the reduced function to increased infection susceptibility no correlation to autoimmunity is mentioned.

In summary, autoimmunity is a prominent clinical feature in CVID. Associated factors include disturbed B and T cell homeostasis and selection, altered antigen receptor signals, increased BAFF levels, and possibly altered TLR signaling. Pathogenic mechanisms, however, have not been identified yet on a molecular level. Further research needs to consider established mechanisms in other genetically defined immunodeficiency disorders to unravel the underlying immune dysregulation in CVID. Our improved knowledge will not only steer potential treatment strategies but also our concept of autoimmunity in general.
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